Half-life, steady state, and accumulation worked through — a second dataset

Half-life, steady state, and accumulation worked through — a second dataset — setting out what I have, and where I think it stops being reliable.

Working through the kinetics rather than the pharmacology, because I think the confusion here is arithmetic.

With a half-life of roughly a week, steady state is approached over four to five half-lives, so anything measured before about a month is measuring a rising concentration. Accumulation at weekly dosing lands the steady-state level near double the first-dose level.

Have I got that right, and does it change what people are actually asking?

Half-life is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.

Terminal half-life estimated from a short sampling window underestimates the true value. That is a common source of discrepant figures between sources.

Somebody will have a better source than mine, and I hope they post it.

Adding a reference point for Half-life. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.

Genuine question rather than a rhetorical one: has anyone here actually observed Half-life, as opposed to read about it? The thread is long and I cannot tell.

Accumulation at steady state: with a week-long half-life, steady-state concentration is reached around 4 to 5 half-lives (about 4 to 5 weeks). Before that, concentration is rising with each dose. The clinical implication: escalating before 4 weeks means escalating before steady state.

This is the answer, and the reason it is the answer is the more useful part.

Confirming post #6 from a second method, which matters more than confirming it from a second person.

A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.

Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance is slowed and accumulation risk is higher. Dose adjustments might be needed.

Albumin binding: semaglutide binds albumin through a fatty side chain, which sequesters the free form and extends the half-life. Tirzepatide also has albumin binding (different mechanism) which extends its half-life compared to an unmodified peptide.

Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

The accumulation ratio for weekly dosing with a week-long half-life is around two, which is why the concentration after several doses is roughly double the concentration after the first.

Genuinely open to being wrong about this one.

Adding a note of thanks rather than an opinion. I did not know most of that.

Post #10 put the caveat in the right place and I want to underline it.

Reading this Half-life thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.